These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
43. The right heart and its distinct mechanisms of development, function, and failure. Markel TA; Wairiuko GM; Lahm T; Crisostomo PR; Wang M; Herring CM; Meldrum DR J Surg Res; 2008 May; 146(2):304-13. PubMed ID: 18036544 [TBL] [Abstract][Full Text] [Related]
44. Regulation of urocortin I and its related peptide urocortin II by inflammatory and oxidative stresses in HL-1 cardiomyocytes. Ikeda K; Tojo K; Inada Y; Takada Y; Sakamoto M; Lam M; Claycomb WC; Tajima N J Mol Endocrinol; 2009 Jun; 42(6):479-89. PubMed ID: 19318426 [TBL] [Abstract][Full Text] [Related]
45. Urocortin 2 infusion in healthy humans: hemodynamic, neurohormonal, and renal responses. Davis ME; Pemberton CJ; Yandle TG; Fisher SF; Lainchbury JG; Frampton CM; Rademaker MT; Richards AM J Am Coll Cardiol; 2007 Jan; 49(4):461-71. PubMed ID: 17258092 [TBL] [Abstract][Full Text] [Related]
47. Involvement of CRH receptors in urocortin-induced hyperthermia. Telegdy G; Adamik A Peptides; 2008 Nov; 29(11):1937-42. PubMed ID: 18775757 [TBL] [Abstract][Full Text] [Related]
48. Beta-adrenergic pathways in human heart failure. Sucharov CC Expert Rev Cardiovasc Ther; 2007 Jan; 5(1):119-24. PubMed ID: 17187463 [TBL] [Abstract][Full Text] [Related]
49. [Nitric oxide in the physiopathology of myocardial dysfunction in heart failure]. Brás-Silva C; Leite-Moreira AF Rev Port Cardiol; 2004 May; 23 Suppl 2():II105-19. PubMed ID: 15222254 [TBL] [Abstract][Full Text] [Related]
50. [Autonomic nervous system in heart failure]. Campelo M; Abreu-Lima C Rev Port Cardiol; 2004 May; 23 Suppl 2():II49-59. PubMed ID: 15222250 [TBL] [Abstract][Full Text] [Related]
51. Emerging drug therapies for the management of acute decompensated heart failure. Tunuguntla A Tenn Med; 2007 Nov; 100(11):33-7. PubMed ID: 18072692 [TBL] [Abstract][Full Text] [Related]
52. Urocortin 2 combined with angiotensin-converting enzyme inhibition in experimental heart failure. Rademaker MT; Charles CJ; Nicholls MG; Richards AM Clin Sci (Lond); 2008 May; 114(10):635-42. PubMed ID: 18052934 [TBL] [Abstract][Full Text] [Related]
53. Natriuretic peptides: biochemistry, physiology, and therapeutic role in heart failure. Stoupakis G; Klapholz M Heart Dis; 2003; 5(3):215-23. PubMed ID: 12783635 [TBL] [Abstract][Full Text] [Related]
54. [Modern therapy of cardiac insufficiency]. Stojsić D; Jelkić N Med Pregl; 1999; 52(3-5):113-24. PubMed ID: 10518395 [TBL] [Abstract][Full Text] [Related]
55. Urocortin: a beneficial or detrimental agent to endothelium? Yang C; Xu Y; Li S Biochem Biophys Res Commun; 2008 Jul; 371(3):345-9. PubMed ID: 18267110 [TBL] [Abstract][Full Text] [Related]
56. The effect of urocortin II administration on the coronary circulation and cardiac function in the anaesthetized pig is nitric-oxide-dependent. Grossini E; Molinari C; Mary DA; Marino P; Vacca G Eur J Pharmacol; 2008 Jan; 578(2-3):242-8. PubMed ID: 17936748 [TBL] [Abstract][Full Text] [Related]
57. Altered beta-adrenergic receptor gene regulation and signaling in chronic heart failure. Port JD; Bristow MR J Mol Cell Cardiol; 2001 May; 33(5):887-905. PubMed ID: 11343413 [TBL] [Abstract][Full Text] [Related]
58. Novel neurohormonal insights with therapeutic potential in chronic heart failure. Dalzell JR; Jackson CE Future Cardiol; 2010 May; 6(3):361-72. PubMed ID: 20462342 [TBL] [Abstract][Full Text] [Related]
59. [The role of uric acid in heart failure]. Alcaíno H; Greig D; Castro P; Verdejo H; Mellado R; García L; Díaz-Araya G; Quiroga C; Chiong M; Lavandero S Rev Med Chil; 2011 Apr; 139(4):505-15. PubMed ID: 21879191 [TBL] [Abstract][Full Text] [Related]
60. New insights into the mechanisms underlying vascular and cardiac effects of urocortin. Díaz I; Smani T Curr Vasc Pharmacol; 2013 Jul; 11(4):457-64. PubMed ID: 23905640 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]